Best In Class

Nurosym is pioneering a new class of technology that uses bioelectrical signals targeted to targeted to the body’s neural circuits, improving health without surgery or drugs. As a clinically focused company founded on science, Nurosym’s primary focus is developing evidence based noninvasive drug-free neuromodulation.

Nurosym at a Glance

Groundbreaking

First CE-Marked non-invasive vagal neuromodulation system

Innovative Investment

$10M invested in clinical research with patented Nurosym technology

Milestone Achievement

Over 3 million treatment sessions successfully completed

Scientific Validation

More than 30 peer-reviewed clinical study publications on Nurosym

Extensive Collaboration

Collaborating with over 60 world-class research partners

Robust Exploration

Over 60 ongoing clinical trials underway

Nurosym Results from 30+ Clinical Trials

Vagus Nerve Activity

61% increase in 5 minutes

Long-Covid Symptoms

Fatigue, Brain Fog, GI Symptoms, Pain

61% improvement

Fatigue

48% improvement

Sleep

19% improvement

Inflammation

78% improvement

Depression Score

45% improvement

Heart Rate Variability

18% increase

POTS Tachycardia

40% improvement

Oxidative Stress

28% reduction

Memory

32% improvement

Reading

29% improvement

Macrocirculation

50% improvement

Microcirculation

39% improvement

Attention Deficiency

11% improvement

Anxiety

35% improvement

Atrial Fibrillation

85% reduction

Heart Muscle Function

19% improvement

GI Symptoms

80% improvement

Results in specific study populations. Individual results may vary.

How does Nurosym Work

The Mechanisms of Nurosym Neuromodulation

Nurosym sends patented electrical impulses to the brain via the Vagus Nerve, with clinical trial results showing:

61% increase in Vagus Nerve Activity & improved Heart Rate Variability

Heart Rate Variability (HRV) is a biomarker of Parasympathetic “rest and digest” system activation, indicating a balanced nervous system often associated with increased vagus nerve activity. In clinical trials, a one-hour session of Nurosym favourably altered three key parameters of Heart Rate Variability (HRV), when compared to placebo. These findings indicate an activation of the parasympathetic 'rest and digest' system, coupled with a decrease in the 'fight or flight' response.

Health implications:
  1. Stress
  2. Anxiety
  3. Exercise recovery
  4. Longevity
  5. Dysautonomia
Source

Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Cardiovascular and Translational Research Independent Clinical Study on Nurosym device, published in PLOS ONE

Figure (A) shows High Frequency HRV is significantly increased (*p=0.001). Figure (B) shows Low Frequency HRV is significantly decreased (*P=0.001). Figure (C) shows the ratio of LF to HF is significantly decreased (*p=0.002). It suggests a greater shift towards the parasympathetic side during Nurosym neuromodulation, indicating a more pronounced relaxation response.

(Figure A, B, C, D) The autonomic function response, Nurosym Neuromodulation favourably altered all HRV parameters (A: HF, B: RMSSD, C: pRR50, D: SDRR). Better effects were observed in people with a poorer baseline HRV ratio. Memory effect was observed, meaning HRV remains elevated after neuromodulation was stopped.

40% improvement in Long-Covid symptoms (fatigue, brain fog, pain)

In a study of patients experiencing chronic fatigue symptoms after Covid-19 infection, approximately 40% of the participants showed positive responses to treatment involving Nurosym neuromodulation, as evidenced by improvements in fatigue, brain fog, and widespread pain. Improvement in long COVID symptoms, such as persistent fatigue, brain fog, and respiratory issues, can enhance quality of life and reduced disability.

Health implications:
  1. Chronic Fatigue Syndrome (ME/CFS)
  2. Stress & Anxiety
  3. Depression
  4. Athletic Recovery
  5. Productivity
  6. Respiratory conditions
Source

Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience

(Figure A) A very significant improvement was observed after 10 treatment sessions. (D0 vs. D10: p < 0.0001). Reserach evaluated our proprietary neuromodulation on those suffering with Long-COVID symptoms such as Fatigue, cognitive problems, Depression, Pain etc. Treatment starts after baseline measurement at Day 0 (D0), ending on D10, with follow up measurements one week later (D17).

78% improvement in Inflammation

Inflammation throughout the body and brain contributes to disease development, progression, ageing, and mental health problems. In a randomised controlled trial of Nurosym neuromodulation, inflammatory cytokines were significantly lower in the group that received Auricular Vagal Neuromodulation Therapy (AVNT) compared to the placebo group at the end of 3 months.

Health implications:
  1. Inflammatory Processes
  2. Aging & Longevity
  3. Muscle Pain
  4. Chronic Pain
  5. Cardiac Conditions (AF, HF, Hypertension)
  6. Mental Health
  7. Autoimmune Disorders
  8. IBS & Other GI Symptoms
Source

Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Clinical Autonomic Research and the Journal of American Heart Association. Reviewed in Nature Reviews Cardiology.

(Figure) The figure presents the changes in the IL-6 inflammatory biomarker compared to placebo.

48% reduced in fatigue & increased energy

Significant improvement in fatigue scores after treatment (D0 vs. D10, p < 0.0001).

Fatigue was measured using the Pichot Fatigue Scale. Participants reported that the improvements in fatigue remained 1 week after stopping the treatment.

Health implications:
  1. Chronic Fatigue Syndrome (ME/CFS)
  2. Productivity
  3. Social functioning
  4. Brain Fog
  5. Sleep quality
  6. Resilience to stress
  7. Pain perception reduction
  8. Long-Covid symptoms
  9. Anti-ageing & longevity
Source

Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience

(Figure) In the study fatigue was assessed using of the Pichot fatigue scale scores during treatment (D0: day 0, D5: day 5 and D10: day 10). The results revealed a substantial reduction in fatigue, registering approximately 48% and higly significant improvment (D0 vs. D10, p < 0.0001) after Nurosym neuromodulation treatment. The individual values and the median are shown.

45% improvement in depression score & improved mood

Nurosym neuromodulation decreased depression score & improved mood in only 5 days of treatment.

The Parasym study revealed that a ten-day treatment regimen of Nurosym led to significant improvements in participants, alleviating chronic symptoms of depression and brain fog.

Health implications:
  1. Memory & cognitive enhancement
  2. Productivity
  3. Brain Fog
  4. Alzheimer’s & Dementia
  5. Social functioning
  6. Long-Covid
Source

Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience

(Figure) The figure shows the evolution of the Beck depression scale (D0: day 0, D5: day 5 and D10: day 10). The results showed a noticeable improvement in mood, registering approximately 45% on the Beck Depression Scale. The individual values and the median are shown.

30% improvement in memory & learning

Nurosym research explores enhancements in memory and neuroplasticity. Improved cognitive function is correlated with the parasympathetic nervous system, whereas cognitive decline is associated with the sympathetic nervous system.

Health implications:
  1. Cognitive enhancement and performance
  2. Memory function
  3. Problem-solving skills
  4. Alzheimer’s & Dementia
  5. Anti-ageing & Longevity
  6. Productivity
  7. Dementia risk reduction
Source

Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Brain Stimulation

(Figure A, B) Nurosym improves memory on learning tasks in comparison to placebo. (A) There was a significant benefit of Nurosym neuromodulation compared to placebo across all test questions. (B) This effect was driven by a significant benefit of Nurosym neuromodulation on memory questions.

(Figure) Nurosym neuromodulation paired with training significantly (*p < 0.05) improved speed performence on the Automaticity learning task compared to placebo controls. Nurosym neuromodulation also significantly (∗p < 0.05) improved percent correct on the Decoding learning task as compared to controls.

40% reduction in POTS symptoms

After two months of using Nurosym therapy, the active group experienced a significant reduction in postural tachycardia syndrome (POTS) compared to the sham group, as observed through heart rate variability analyses. Additionally, the active group showed lower levels of anti-autonomic autoantibodies (specifically α1-AR and β1-AR), indicating a potential improvement in autonomic function and a reduction in inflammation.

Health implications:
  1. Decreased inflammation
  2. Improved heart rate & rythm regulation
  3. Recuded risk of cardiovascular complications
  4. Post-trauma recovery
  5. Arrhythmias mitigation
  6. Oxygen level increase
Source

Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology. Independently evaluated and funded, published in Journal of the American College of Cardiology

50% improvement in blood vessel flexibility & improved circulation

Nurosym has demonstrated the ability to enhance blood circulation compared to a placebo. This improvement in blood circulation, or perfusion rate, is crucial for efficiently supplying oxygen and nutrients to tissues while removing waste products. Such enhancements contribute to overall health and longevity by optimizing blood supply to various organs.

Health implications:
  1. Oxygen and nutrient delivery to tissues
  2. Organ function
  3. Blood clots risk reduction
  4. Vascular disease risk reduction
  5. Varicose veins
  6. Fatigue
Source

Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently funded & evaluated, peer reviewed & published in Journal of Cardiovascular Pharmacology

(Figure (A, B, C): (A) Pseudo color images on dorsum of left hand during (1) baseline, (2) occlusion, and (3) Postocclusive reactive hyperemia (PORH) phase. Blue color represents lower, red represents higher perfusion rates. (B, C) Changes in blood perfusion measured over nail bed area, before and after Nurosym neuromodulation (B) and sham (placebo) stimulation (C). Markedly higher perfusion rate was seen after Nurosym neuromodulation

If you are a healthcare professional and would like to learn more about our clinical studies, science or recommended protocols, apply for our Healthcare Professional Program.

Apply here

Learn more about Nurosym research studies.

Go to parasym.co

Meet the Doctors

Dr. Elisabetta Burchi - Nurosym

Dr. Elisabetta Burchi, MD, MBA

Translational research lead at Parasym

A practicing doctor of psychiatry, Dr Burchi is an expert in neuromodulation with deep research and clinical experience in the field. Dr Burchi also holds an MBA from INSEAD and formerly worked at the Albert Einstein School of Medicine in New York. A leader in patient care, neuroscience research, communication and management. Dr. Burchi is a physician-scientist, working with Parasym in clinical affairs with a track record of publishing in the most important scientific journals such as The Lancet, writing successful grant proposals for the NIH, and leading the production of editorial, clinical, regulatory and promotional material in collaborative multidisciplinary teams. Dr. Burchi has also coordinated clinical trials and implemented a tele-medicine practice which received a certification of excellence among more than 100,000 professionals.